Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is one of the most common — and most frustrating — urological conditions. Approximately 9.3% of men will be affected during their lifetime, yet diagnosis still relies heavily on subjective symptom scores, and conventional therapy often provides limited relief. In a review published in iMetaMed, researchers argue that this impasse stems from an outdated, prostate-centered view of the disease.
Traditionally regarded as an isolated inflammatory disorder of the prostate, CP/CPPS is now recognized as a complex, systemic syndrome. Beyond pelvic pain, patients frequently experience widespread pain, sensory hypersensitivity, depression, anxiety and pain catastrophizing; epidemiological and genetic studies link the condition to metabolic and autoimmune diseases. The review organizes this clinical heterogeneity within a unified neuro-immune-metabolic-microbiota axis.
Evidence across the four axes converges on a coherent story. Prostatic epithelial pyroptosis (NLRP3/GSDMD) initiates local inflammation; peripheral and central sensitization — driven by NGF/TrkA signaling, spinal glial activation and remodeling of the brain pain matrix — chronicizes pain; immune-metabolic reprogramming, including M1 macrophage polarization and Th17 bias, couples inflammation to diet, sleep and stress; and gut dysbiosis acts through metabolites such as short-chain fatty acids, bile acids and 5-HIAA to shape systemic immunity. Mendelian randomization studies add genetic evidence for a causal gut-prostate axis.
Building on this framework, the authors propose precision diagnosis that goes beyond traditional prostatic-fluid analysis — combining candidate biomarkers such as NLRP3, multiparametric MRI and symptom-based stratification models — together with an axis-rebalancing treatment strategy built on three pillars: neuromodulation, immune-metabolic intervention and microbiota-targeted therapy. A four-step roadmap links multi-omics patient profiling to subtype-guided multimodal therapy, aiming to restore axis homeostasis.
The review calls for multimodal diagnostic tools and mechanism-stratified prospective trials to validate interventions targeting key axis hubs. Ultimately, the authors conclude, CP/CPPS should be managed as a systemic sensory-immune-metabolic disorder, moving management from empirical treatment toward individualized precision medicine.
iMetaMed
Literature review
People
Chronic Prostatitis / Chronic Pelvic Pain Syndrome: Research Progress and Precision Diagnosis-Therapy under the Integrated Neuro-Immune-Metabolic-Microbiota Axis Framework
27-Oct-2026
The authors declare no conflicts of interest.